A new study confirms that patients who received Eylea over two years achieved visual improvements with fewer treatments, compared to those receiving an alternative medication. Following a three-year international study at Retina Health Center and centers around the world and approval by the Food and Drug Administration (FDA), Eylea is now offered as an available treatment option for wet age-related macular degeneration (AMD).